|Poll|October 31, 2014

Mini-quiz: Treatment-Resistant Depression

What percentage of depressed patients are resistant to treatment with conventional antidepressant medication?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms

ByJessica Walters

August 5th 2026

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

ByPragyan Sharma, MD, MSc,Samara White, PharmD,Ranel Troy Santos, PharmD, BCPP

August 5th 2026

Effective Prescription of Exercise for the Treatment of Depression and Anxiety

ByPrerna Gait, MD

August 4th 2026

Centanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD

ByRaman Baweja, MD

August 3rd 2026

Reframing the Side Effect: Walter Brown, MD, on Placebo and Nocebo

ByJoseph F. Goldberg, MD,Walter A. Brown, MD

July 31st 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Mini-quiz: Treatment-Resistant Depression

Related Content

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

Effective Prescription of Exercise for the Treatment of Depression and Anxiety

Centanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD

Reframing the Side Effect: Walter Brown, MD, on Placebo and Nocebo

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

Postpartum Psychosis on Trial: What the Lindsay Clancy Case Can Teach Us

Bringing Wearable Data Into Psychiatric Care: Amae Health Partners With Google Health Enterprise to Improve Outcomes

Centanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD